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Principles that govern cell shape change, govern tissue development and regeneration and 
provide a model for understanding diseases including cancer. Due to the overexpression 
of CLP36 and ACTN4 in other cancers, I hypothesized that the interaction between 
ACTN4 and adaptor protein CLP36 in pancreatic cancer cells has a role in migration and 
cell shape morphology. Cell migration assays, including scratch wound and transwell 
assays, were used to assess the migration of metastatically derived pancreatic cancer 
cells; depletion of clp36 decreases cell migration and invasion in vitro. 
Immunofluorescence was used to assess the localization of CLP36 at the cell edges. 
CLP36 localizes in actin protrusions in metastatically derived pancreatic cancer cells. 
These results suggest that CLP36 is an important regulator of pancreatic cancer cell 
migration. This study provides information on CLP36 in cell migration, CLP36 
expression and its possible contribution to the progression of pancreatic cancer. Also, this 
approach provides information on the power of upregulation and downregulation of 
proteins in pancreatic cancer suggests strategies for manipulating the proteins to treat 
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Chapter 1: Cell Behavior and the Cytoskeleton 
 
Cells and tissues derive their functions from their shapes, adhesion and motile 
characteristics, and structural integrity.  These morphological features are derived from a 
highly integrated network of structural and signaling proteins. Signaling proteins direct 
the structural proteins, but in turn, the structural proteins sense mechanical inputs and 
feed this information back onto the signaling pathways.  In the sections below, the key 
elements discussed are proteins in the cytoskeleton and cell behavior that leads to cell 
invasion and migration. Cell migration can lead to cancer cell metastasis or invasion into 
healthy host tissue. Learning about the cellular and molecular basis of migration and 
invasion in cancer cells will help us understand how cancer cells spread and can lead to 
new treatment strategies.  
 
1.1.1 Actin 
Actin is a protein that assembles into microfilaments, one of the components of 
the cytoskeleton. Actin is present as a free monomer, G-actin, or as a linear polymer, F-
actin. The polymeric form is generally the functional form, but pools of G-actin are 
necessary to build polymers when and where the cell requires them.  Dynamic actin 
filaments are essential for many cellular functions, such as processes like muscle 
contraction, cell motility, signaling, cell division and cell shape. The epithelial-
mesenchymal transition in metastatic cancer cells is regulated by the remodeling of actin 
[3]. Actin remodeling is a process that allows for alterations of cellular organization. 
Actin-binding proteins aid in the alteration of actin filaments. Actin monomers join the 
positive end of the filament in the ATP state, while ADP-actin monomers dissociate from 
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the negative end in a process called treadmilling. Actin polymerization and de-
polymerization are dependent on the conversion of G-actin to F-actin and hydrolysis of 
the ATP. The concentration of G-actin and F-actin continuously fluctuate and the 
assembly and disassembly of F-actin will undergo treadmilling [4]. Superimposed upon 
the intrinsic dynamics of actin polymer assembly and disassembly, the cell uses many 
actin binding proteins, which further modulate the actin cytoskeleton dynamics, 
increasing the richness and control [5]. Actin binding proteins have many different roles 




Alpha-actinins are necessary for the cross-linking of filamentous actin in the 
cytoskeleton to protect cells from mechanical stress and control cell movement. The 
interactions between alpha-actinin and proteins regulate cell adhesion and motility. 
Alpha-actinin is a family of cross-linking proteins that includes four paralogous family 
members: alpha-actinin-1 (ACTN1), alpha-actinin-2 (ACTN2), alpha-actinin-3 (ACTN3) 
and alpha-actinin-4 (ACTN4). The muscle-associated actinins are ACTN 2 and ACTN 3, 
while non-muscle isoforms are ACTN1 and ACTN4. The muscle isoforms are found in 
skeletal and smooth muscle and organize actin filaments into sarcomeric structures, 
which constitute the minimal contractile unit. The non-muscle paralogs organize actin 
filaments into the networks that contribute to non-muscle cell structure, migration and 
adhesion. ACTN4 has been linked to metastasis in cancer through cellular features and 
cellular misbehavior [6-9]. 
 3 
ACTN4 regulation and interactions have been shown to have a role in cancer cells 
and metastasis. ACTN4 has been studied in the context of lung cancer metastasis to the 
brain. ACTN4 expression is prominent in metastatic brain tumors, but not primary lung 
cancer tissue [10]. Lung cancer metastasis to the brain is due to the interaction of ACTN4 
with actin reorganization in the cytoskeleton, cell motility and focal adhesion [10]. 
Patients with an increase in the copy number of ACTN4 have metastatic phenotypes 
leading to lower prognosis, like salivary gland carcinoma [11]. Studies with animal 
models have shown ACTN4 as an important regulator of cell motility. Specifically, in 
murine lung fibroblasts, ACTN4 is significant in cell behavior like migration, spreading, 
adhesion and proliferation [12]. Knocking down ACTN4 impairs fibroblasts in cell 
migration, spreading adhesion and proliferation, suggesting that ACTN4 is necessary for 
normal cell morphology and motility [12]. ACTN4 enhances cancer cell motility, 
invasion and metastasis. Focal adhesions are dynamic protein complexes through which 
the cell’s cytoskeleton connects to the extracellular matrix. In colorectal cancer cells, 
ACTN4 provokes immature focal adhesions which leads to cell motility and invasion, 
while ACTN1 does not [13]. Findings have suggested that alpha-actinins are linkers 
between cytoskeleton and integrin’s and participate in force transmission at adhesion 
sites to facilitate adhesion growth [60]. ACTN4 works with cytoskeleton proteins and 
overexpression of ACTN4 functions to promote breast cancer tumorigenesis through cell 
motility [14].  
 4 
1.2 CLP36/PDLIM1/CLIM1 
Due to the association of alterations between actin and alpha actinins in cancer, 
another protein called CLP36 is of interest in cancer cells because it interacts with alpha 
actinins. CLP36 has been shown to associate with actin filaments during shape change, 
migration and contraction of endothelial cells. As discussed before, cytoskeletal proteins 
are important regulators of cell migration in metastatic cancer. CLP36 (a.k.a. CLIM1, 
PDLIM1, or Elfin) is a 38 kD protein that has an N-terminal PDZ domain and a C-
terminal LIM domain. CLP36 is expressed in the heart, lungs, liver, spleen, colon, 
vasculature, and blood and is found in epithelial and endothelial cells. During cell shape 
change events, including spreading, migration and contraction of these cells, CLP36 
associates with actin filaments and stress fibers [1, 2].  CLP36 binds to two paralogous 
actin crosslinking proteins, non-muscle alpha-actinin-1 and alpha-actinin-4, which 
associate with actin structures involved in key cellular processes, like cell shape change, 
migration, polarity, and cytokinesis. High expression of alpha-actinin 4 in the colon and 
CLP36 have been found to specifically interact in colon epithelial cells through an 
ACTN4-CLP36 complex. The complex extends to the actin stress fibers of the non-
muscle cells [2]. The association of CLP36 and ACTN4 in actin stress fibers is relevant 
to cancer cell migration and metastasis.  
 
1.3 LIM domain proteins  
 
LIM domain proteins regulate gene expression, organization of cytoskeleton 
proteins, determination of cell fate, and formation of tumors. LIM domain proteins act as 
adaptors to support the association of protein complexes. LIM domains are 50-60 amino 
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acids long and contain two conserved zinc motifs. The two zinc fingers contain eight 
cysteine and histidine residues [15]. 
LIM domains are found in other proteins related to nuclear and cytoplasmic 
proteins. The proteins that are localized to the nucleus contain two LIM domains and are 
named LIM only proteins (LMO). LMOs are common in genes that are activated by 
translocations that can occur in hematopoietic cancers and mesenchymal tumors [16]. 
Also, LIM domains are found in kinases like Lmk1 and Lmk2 [17, 18]. PDZ-LIM 
proteins like CLP36 have been suggested to act as adapters between kinases and the 
cytoskeleton. The LIM domain containing proteins have important roles in biological 
processes like cell fate decisions and organ development [19]. The interaction between 
ACTN4, CLP36, and actin can lead to changes in cell behavior and migration which can 
promotes cancer.  
 
1.4 Cell Behavior 
 
1.4.1 Cell adhesion 
 
Cells have a variety of properties including the ability to adhere to surfaces or to 
neighboring cells.  Cells have special proteins called cell adhesion molecules that allow 
cells to stick to each other (e.g. E-cadherin) and their surroundings (e.g. integrins).  
Adhesion proteins are organized into cellular adhesion structures such as focal adhesions, 
which mediate adhesion to surfaces, and adherens junctions, which mediate adhesion to 
neighboring cells [20]. An additional role of focal adhesions and adherens junctions is to 
detect forces (including resistive tensile forces) that emanate from the extracellular 
matrix [21] or that are exerted by surrounding cells [22]. The active components of 
tensile forces are generated by the cell’s cytoskeleton, including contractile myosin II 
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motors and actin polymer remodeling, and are regulated in part by signaling cascades 
[23].  
The disturbance of epithelial cells results in pathologies like fibrosis and cancer 
[24]. Defects in cell adhesion can lead to carcinogenic processes such as epithelial-to-
mesenchymal (EMT) transitions [24]. EMT is the disturbance of epithelial cell polarity 
and reduction in adhesion, providing cells with increased ability to migrate and invade. 
Signaling pathways that generate EMT induce E-cadherin (major cell-cell adhesion 
protein) repressors like the Snail genes [25, 26]. Changes in the cell increase the ability to 
migrate through a range of environments with varying stiffnesses [27, 28]. Tissue 
stiffness variations are associated with cancer and often increase due to changes in the 
extracellular matrix composition during tumor growth, further disrupting the forces 
between epithelial cells and the extracellular matrix and promoting metastatic migration 
[29, 30]. Loss of cell adhesion complexes may lead to spreading of cancer due to loss of 
contact and anchoring to the extracellular matrix.  
 
 
1.4.2 Cell division 
Cell division in mammalian cells occurs through activation and deactivation of 
proteins that regulate the phases of the cell cycle. Here, I provide a concise summary of 
the process. The cell cycle contains five phases: G0 (non-cycling quiescent phase), G1 
(growth phase 1), S (synthesis), G2 (growth phase 2), and M (mitosis). The first four 
phases are called interphase. In G0, the cells are in a resting state and some cells maintain 
this state for their lifespan. Growth factors stimulate cells to enter G1 and then into S 
phase where DNA is replicated. In the S phase, DNA replication is largely completed, 
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and the cell prepares to undergo mitosis. During mitosis, the chromosomes are separated, 
and the cell divides itself into two daughter cells during cytokinesis. Mitosis is broken 
down into five sub-phases: prophase, prometaphase, metaphase, anaphase, and telophase. 
Throughout the cell cycle, cellular surveillance systems ensure that only healthy cells 
multiply. When an error is found, a checkpoint control is activated, which prevents the 
cell from progressing until the error is corrected [31].  Importantly, loss of cell cycle 
control can lead to human cancer due to check point errors accumulating, resulting in 
proliferation and instability in the genome. Cancer cells have mutations that can lead to 
cyclin-dependent kinase (CDK) hyper-activation. About 30 cyclin-dependent kinase 
inhibitors have been developed to target these kinases [31]. Inhibitors of CDKs, can 
induce cell-cycle arrest. There is extraordinary interest in targeting the cell cycle through 
inhibition, including the CDKs, for the development of anti-cancer drugs.  
 
1.4.3 Cell Invasion and Migration  
 
Cell invasion is a result of the ability of cells to be motile and navigate through 
the extracellular matrix. Cells demonstrate a variety of types of movement, including 
migration of cells on a surface or tissue, migration of cells into a wound during wound 
healing, and cell division. Another example of cell movement is contraction which is 
responsible for the function of muscle cells and the separation of daughter cells during 
cell division. Motors pull membrane tubes along cytoskeletal filaments which allows for 
contraction. During migration, rapid polymerization of the cytoskeleton by adding 
subunits to the end allows for cell movement. As seen in the schematic drawing in figure 
1, the protrusion of a lamellipodium is controlled by the polymerization of actin filaments 
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at the leading edge, allowing for protrusions of the front end of migrating cells where 
actin (seen in red) is accumulated. The membrane is extended forward by the pushing of 
the actin filaments, thus allowing for cell body movement. Once the membrane has 
extended the membrane becomes attached to the surface and a new adhesion is formed. 
After forward extension of the front of the cell, the cell body is moved forward and de-
adhesion (focal adhesions are broken) occurs at the rear of the cell which completes the 
forward movement of the cell (Fig. 1). 
 
 
Figure 1. Model of Cell Movement 
This schematic drawing shows cell movement primarily driven by actin. A) Extension: 
motility is initiated by actin protrusions at the cell’s leading edge. B) Adhesion: 
protrusion of the leading edge will allow for a new adhesion. C) Translocation: the cell 
body contracts which causes retraction of the rear and forward movement of the cell 
body. D) De-adhesion: the cell will detach from the surface to which it was adhering. 













1.4.4 Cancer Metastasis 
 
1.4.4.1 Endothelial-mesenchymal transition (EMT) 
 
In metastasis, cancer cells travel through the blood or lymph system and form new 
tumors in other parts of the body. Steps that cancer cells undergo to metastasize are: 
breaking away from original tumor, traveling to other parts of the body, growing in the 
new location and avoiding attacks from the immune system. Movement of cancer cells 
and seeding of new tumor cells in tissues is a process called invasion-metastasis cascade 
[32, 33]. Several types of carcinoma cells can obtain secondary tumor capability through 
epithelial-mesenchymal transition including pancreatic [34], prostate [35], breast [36], 
ovarian [37], and renal [38]. Many cancers result from epithelial tissues where 
abnormalities in cell-cell and cell-matrix interactions occur during tumor development. 
The epithelial-mesenchymal transition schematic drawing (Fig. 2) derived from Jean Paul 
Thiery’s model of epithelial-mesenchymal transition represents the process of how cells 








1.4.4.2 Mesenchymal-epithelial transition (MET) 
Differentiated carcinomas tend to grow and spread more slowly than poorly 
differentiated cancer cells and often re-differentiate by mesenchymal-epithelial re-
transition (MET). The EMT-MET switches suggest a motivating force of metastasis [40]. 
Invasive cancer cells arrested in growth phase and proliferation occurred in re-
differentiated metastasis, suggesting that EMT needs to be reversed for the cell to grow 
and colonize [40], supported by EMT inducing transcription factors that can prevent 
proliferation [41]. EMT-MET switches in metastasis have been suggested that this 
transition is important for secondary tumor growth [42, 43]. There is strong evidence for 
Figure 2. Epithelial-Mesenchymal Transition 
Schematic drawing of normal epithelial cells showing loss of cell adhesion (carcinoma) and 
cell polarity, allowing the cells to gain migratory properties. The cells undergo EMT and 
become invasive and can travel through the blood vessel through processes of intravasation 
and extravasation. After, the cells transition into epithelial properties which involves the 




EMT-MET switches in embryonic systems, but in human cancer, the MET event is still 
unclear [39].  
Understanding EMT-MET switches can lead to further understanding of the 
progression of cancer. Studying metastatic cancers can pave the way to stop or prevent 
the metastasis of primary cancer cells. Current treatments and drugs are focused on 
preventing or relieving symptoms. Since every patient is different, it is important for 
ongoing research to study cell morphology, behavior, and proteins associated with cancer 
to then apply this knowledge to diseases so that it paves the way for patient-specific 
targeted therapy. 
Cancer is an illness in which characteristics of cell behavior are lost or disturbed. 
Uncontrolled cell proliferation, migration, invasion, and cell morphology are common 
features of cancers. Actin, alpha-actinins and CLP36 are key players that reinforce these 
cellular processes. Abnormal expression of cytoskeletal associated proteins play an 
important role in the ability of cancer cells to metastasize and resist drug therapies, 
understanding this role will help with future drug therapies and prognosis.  
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Pancreatic cancer is a deadly disease that affects about 55,000 people in the United 
States and is usually not detected until later stages (poor prognosis). The best chance of 
successful treatment is when the cancer is detected early.  Research is focused on 
approaches that may help to detect earlier stages before it spreads. Also, research is 
focused on identifying mutated genes and proteins that may be causing abnormal changes 
in the cells. This information will be useful in developing new drugs that target abnormal 
changes, as well as a possibility to screen for the cancer in individuals that are at high risk 
for developing the disease. Thus, in vitro studies like cell migration assays are important 
because they provide the foundation that leads to in vivo studies in animal models that 
can lead to targeted therapy.  
 
 
1.1.1 CLP36, alpha actinins and PDZ-LIM interactions 
Studies have tried to identify proteins that induce macromolecules that recognize 
antibodies in patients with pancreatic cancer because the identification of tumor antigens 
can potentially provide a detection for early diagnosis. CLP36 is a protein that is 
recognized by the immune system in patients with pancreatic adenocarcinomas [46]. 
Additionally, CLP36 suppresses epithelial to mesenchymal transition in colorectal cancer 
cells by stabilizing beta-catenin [47]. CLP36 and PDLIM4 (PDZ and LIM domain 
protein 4) both are actinin-associated LIM proteins that have roles in forming stress fibers 
in fibroblasts by recruiting alpha-actinin-1 [48]. 
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CLP36 has a PDZ (N-terminal) domain and LIM (C-terminal) domain. PDZ-LIM 
proteins act as adapters for cytoskeleton proteins and kinases [49, 50]. Through the PDZ 
and LIM motifs, proteins can associate with cytoskeletal and signaling proteins [51]. 
More specifically, PDZ domain interacts with the cytoskeleton [49, 50, 52, 53] and the 
LIM domain interacts with kinases [50, 54, 55]. Most of these studies have been 
performed in muscle due to high expression of PDZ-LIM proteins in the muscle. ACTN2 
and ACTN3 are muscle specific, which anchor actin thin filaments at the Z lines in 
striated muscle and dense bodies in smooth muscle [56]. On the other hand, there are two 
non-muscle actinins, apha-actinin-4 and alpha-actinin-1, which are less concentrated at 
stress fibers and detected in focal adhesions. Expression of alpha-actinin-4 is prompted in 
migrating cells [8]. CLP36 is expressed in non-muscle tissues with low expression levels 
in the pancreas [57]. In addition, CLP36 is highly expressed in epithelial cells, localizes 
to actin stress fibers through the PDZ domain, and interacts with alpha-actinin-1 and 
alpha-actinin-4 [2]. 
 
1.1.2 Pancreatic cancer 
Pancreatic cancer arises when cells in the pancreas begin to multiply 
uncontrollably and form a mass and then metastasize to other parts of the body. There are 
different types of pancreatic cancer. Pancreatic adenocarcinoma starts within the 
epithelial lining of the pancreatic ducts. Non-adenocarcinoma, another type of pancreatic 
cancer arises from hormone-producing cells of the pancreas. Non-adenocarcinoma is less 
aggressive than pancreatic adenocarcinoma. Patients with pancreatic adenocarcinoma 
usually show no symptoms during the early stages, and symptoms do not develop until 
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the disease reaches a stage where it spreads to other parts of the body [44], including 
nearby lymph nodes, liver, peritoneal cavity, large intestine or lungs [45].  Therefore, 
pancreatic adenocarcinoma is one of the most lethal diseases with only ~6-7% of patients 
surviving to 5 years. 
CLP36 may be an adaptor between actin stress fibers and LIM-binding proteins. 
The low expression level of CLP36 in the pancreas and that it interaction with alpha-
actinins it led me to my initial question: Is CLP36 overexpressed in pancreatic cancer 
cells? Preliminary data suggests that CLP36 is highly expressed in human metastatic 
pancreatic cancer cells (AsPC-1). Then, I asked if CLP36 overexpression is associated 
with the migration of cells that lead to metastasis. Recent findings demonstrate that high 
levels of CLP36 in breast cancer is associated with cell migration and metastasis [58]. Is 
CLP36 necessary to drive migration behavior in AsPC-1 pancreatic cancer cells? Is 
overexpressed CLP36 sufficient to drive migration behavior in cancer cells? I 
hypothesized that if CLP36 interacts with alpha-actinin-4, then knock down of CLP36 



















Cells and Cell Culture 
Human ascites derived pancreatic cancer (AsPC-1) were purchased from ATCC 
and grown in RPMI 1640, L-Glutamine media (Gibco), supplemented with 1% penicillin 
and streptomycin, 10% FBS (ATLAS Bio), and insulin (4mg/mL). Cells were detached 
using 0.5% trypsin (Life Technology). 
Human primary tumor-derived cells (Panc10.05), Human pancreatic ductal 
epithelial cells (HPDE) were obtained from Dr. Ming-Sound Tsao (University of 
Toronto, Ontario Canada), human primary tumor-derived cells (Panc10.05) and human 
metastatically-derived cells (AsPC-1) were purchased from ATCC.  
 
Engineered cell lines 
Lentiviral knockdown cell lines were generated in AsPC-1 parental strains. For 
lentiviral knockdown, the hairpins used (Sigma Mission shRNA) were:  
(A) 3UTR1238S21C1, (B) 3UTR1238S1C1, (C) 3UTR1183S1C1, (D) CDS869S1C1, 
(E) CDS669S1C1, (Vector) pLK0.1 as control 
Target plasmids were co-transfected with envelope plasmid such as pCMV-VSV-
G and pCM-dR8.2, via Transit 20/20 (Mirus) transfection reagent into Lenti-X HEK293t 
cells. Sixteen hours post transfection, the media was changed to fresh DMEM (10% 
FBS/1% penicillin streptomycin). Media containing virus was harvested after 24 hrs 
lentiviral infection to infect AsPC-1 cells. Positively infected AsPC-1 cells were then 
selected for with 5 mg/ml puromycin for 3 days by kill-curve analysis. Knockdown of 
CLP36 was confirmed with western analysis and Coomassie staining. AsPC-1 cells with 
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CLP36 knockdown were fixed for confirmation through cell imaging. Transfection 
efficiency of CLP36 was optimized in AsPC-1 with a 3:1 ratio using Mirus Transit IT 
2020 reagent in reduced serum media- OptiMEM (GIBCO). 
 
Cell Lysis and Western Blot Analysis 
Cell extracts were lysed in RIPA buffer containing 1:100 Protease inhibitor cocktail, 
1:100 RNase, 1:100 phenylmethylsulfonyl fluoride (PMSF), 1:1000 Aprotinin. 
Concentration of proteins was determined using Bio-Rad Bradford assay. Proteins were 
separated on SDS-polyacrylamide gels and transferred onto nitrocellulose membrane 
(Bio-Rad). After incubation with 5% milk in phosphate buffered saline with Tween-20 
(PBST), the blots were probed with primary antibodies. The antibodies used were rabbit 
polyclonal PDLIM1/CLP36 1:5000 (Proteintech) and GAPDH mouse monoclonal 1:1000 
(Proteintech). Fluorescently labeled secondary antibodies used were 680 nm Goat-anti-
mouse (1:10,000), 800 nm Goat-anti-rabbit (1:10,000) (Licor). Signals were detected and 
quantified on the LI-COR Infrared Imaging System.   
 
PCR 
Total RNA of ASPC cells was isolated with a TRIzol reagent. Reverse 
transcriptase-GoScript Reverse Transcription system (PROMEGA) was used to create a 
cDNA library. 
PCR cloning was performed on the cDNA library using a ViiA7 Realtime PCR 
System (Applied Biosystems). Primer sequences used here:  
5'-AAAAAAGTCGACATGACCACCCAGCAG-3' (mCherry N1),  
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5'-AAAAAAACCGGTCGCTTGGGGAACACAG-3' (mCherry N1)  
PCR purification was done using QIAquick PCR purification kit (QIAGEN), PCR 
product ran on an agarose gel to confirm and extract bands using glass milk or QIAquick 
gel extraction kit (QIAGEN).  
 
Constructs 
Restriction digest was performed on vectors pmCherry N-1 and PCR product 
(CLP36). Ligation was performed using 10X T4 DNA Ligase Buffer and T4 DNA 
Ligase. Transformation was performed with in-house competent STBL2 E. coli cells, and 
cells were plated on kanamycin plates (50 mg/mL) followed by overnight incubation at 
30 C.  Minipreps were performed using glass milk and QIAgen DNA purification kit 
(QIAGEN). Constructs were sequenced at the Synthesis and Sequencing Facility at JHMI 
using Sanger Sequencing with the PCR primers. Additional primers were used along with 
the PCR primers to confirm that the DNA sequences in the constructs are correct. 
Forward: 5'-CCAGAGGAGACCAGAC-3' 
Reverse: 5'-TGCTCAGAAGTTGCCTATG-3' 
 After confirmation of correct construct, maxi-prep was performed using glass 
milk to obtain high concentration of construct. 
 
Cell assays 
2D random migration/Scratch wound assay 
AsPC-1 cells were plated at a sub-confluent concentration in a 24-well tissue 
culture plate. Cells were serum starved for 24 hours. After starvation, cells were 
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scratched using a micropipette tip (3 scratches per well) and stimulated by changing to 
PANC media. For 16 hours following scratching, cells were tracked using the High 
content imager (IXM) at the Microscope facility at JHMI.  
 
Transwell assays  
AsPC-1 cells were plated in 6.5-mm PET membrane transwell inserts with 8-µm pores 
(Costar #3464) in a 24-well plate with 5,000 cells per well. Cells were allowed to adhere 
overnight in PANC media. Cells were washed with PBS, then cell media was changed to 
serum-free RPMI 1640 to starve cells for 24 hrs (top chamber and well). After starvation, 
cells were stimulated by changing media to PANC media in the well (bottom part of 
chamber). Cells were incubated for 24 hrs at 37 degrees C/5% CO2 and then fixed in 4% 
paraformaldehyde, permeabilized with 0.1% Triton X-100 and stained with 1 μg/ml 
DAPI. Before imaging, the top chamber was swabbed with a cotton-tip swab and washed 
to remove cells that did not translocate. A total of five random fields per transwell insert 




Cells used were AsPC-1 parental control, knockdowns (A and B) and vector control. 
Cells were seeded onto collagen coated slides (rat tail collagen 3 mg/mL). Primary 
antibodies used were 1:1000 Clp36 rabbit 1:1000 (Proteintech), ACTN4 mouse 1:500 
(SANTA-CRUZ). Secondary antibodies used were Alexa Fluor 488 goat-anti-mouse 
(green) (1:500), Alexa Fluor 568 goat anti-rabbit (red) (1:500), Alexa Fluor 647 goat-
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anti-mouse (far-red) (1:500). Stained the cells nuclei with DAPI (1:1000) and fluorescein 
isothiocyanate- (FITC) phalloidin stain for actin (1:500) using the LEICA spinning disc 
and Zeiss 510 laser-scanning microscopes. 
 
Live-cell microscopy 
Cells were isolated and plated onto a collagen-coated 35-mm dish and cultured for 
24 hrs before imaging. Time-lapse images were acquired with a 3I spinning disk 
microscope equipped with a heated chamber and CO2 controlling unit. Time-lapse 
sequences fluorescence images were collected at three stage-position sites every 10 min 
for 16 hr.   
 
Statistical analysis 
Statistical analysis was performed using KaleidaGraph (Synergy Software). 
Significance of differences were identified using ANOVA with a Fisher’s least 




















To determine what cell line to use for my project, western analysis was performed 
to assess CLP36 expression in different cell lines. The human-derived lines included 
HPDE (immortalized Human pancreatic ductal epithelial cells), Panc10.05 (stage II 
pancreatic adenocarcinoma-derived), AsPC-1 (stage IV ascites-metastasis-derived) and 
HTC116 (colorectal carcinoma). The results suggest that CLP36 is highly expressed in 











To test CLP36 as an important regulator of cell migration, I performed 
immunofluorescence on AsPC-1 cells to determine the localization of endogenous CLP36 
when the cells are seeded on collagen for higher adhesion to the cell culture surface. 
CLP36 localizes to cell edges, while actin appears all over the cell and cell edges. Actin 
shows a stronger fluorescence at the areas where CLP36 is also enriched (Fig. 4). 
Figure 3. Expression of CLP-36 in Pancreatic Cell Lines 
Western analysis was performed with antibodies against CLP36, ACTN4 and GAPDH in 
different cell lines. GAPDH was used as a loading control. The pancreatic cell lines used 
were (HPDE-human pancreatic duct epithelial cell line, Panc10.05-non-metastatic pancreatic 
adenocarcinoma, AsPC-P-metastatic pancreatic adenocarcinoma) and HTC116-colorectal 





CLP36 was knocked down using shRNA in AsPC-1 cells to test whether CLP36 
is necessary for cell migration. Western analysis showed that shRNA knockdown was 





The shRNA constructs “A” and “B” were selected for future experiments because 
they effectively knocked down CLP36 and are the untranslated region (UTR) and the 
coding region (CDS), respectively. The untranslated region of mRNA is involved in gene 
expression and can contribute to mRNA stability and protein translation. However, the 
Figure 5. Assessing efficiency of knockdown 
Western analysis using antibodies against CLP36 to evaluate knockdown of CLP36 
by several shRNAs (A-E). GAPDH was used as a loading control.  
Figure 4. Localization of Endogenous CLP36 
Immunofluorescence microscopy of ASPC cells fixed on collagen and labeled with CLP36 
(red), FITC phalloidin for actin (green) and the nuclei (blue) were labeled with DAPI.  
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coding region, as the name implies, directly encodes the proteins.  Thus, while both are 
useful for studying the loss of function phenotypes, shRNAs that target the UTR can then 
be used for rescue experiments with plasmids that can encode the protein.  Such future 
rescue experiments are invaluable to ensure that the observed effect is due to knockdown 
of CLP36 and not due to off-target effects. Further confirmation of knockdown was 
assessed by immunofluorescence staining of CLP36. Actin and the nucleus were also 
stained. Cells treated with shRNAs “A” and “B” both have less fluorescence intensity for 
CLP36 as compared to AsPC control (no treatment) and the negative/vector control (Fig. 
6). 
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Figure 6. Knockdown of CLP36 in AsPC cells 
Immunofluorescence of fixed cells on collagen stained with CLP36 (red). Fluorescence 







To test whether knockdown of CLP36 affects migration in AsPC cells, scratch 
wound assays were performed (Fig. 7a), and cellular morphology, such as the formation 
of lamellipodia, and the ability of the cells to migrate, was analyzed (Fig. 7b). Both 
knockdowns “A” and “B” showed significantly decreased average distance traveled by 
the cells (Fig. 7c). Average distance traveled by shRNA A treated cells compared to 
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control was decreased (p<0.0002). ShRNA B also traveled less than the control 
(p<0.0005). When shRNAs A and B were compared to the vector control, the distance 




Figure 7. Scratch Wound Assay: 
Average Distance of CLP36 
Knockdowns  
(A) Diagram representing scratch 
wound assay. (B) Morphology of 
migrating cells from the time-lapse 
microscopy of the scratch wound 
assay (zoomed in picture showing 
cells protrusions), the white arrows 
are showing lamellipodia. (C) Dot 
plot showing the average distance 
moved of AsPC cells in different 
conditions, each dot represents the 
average distance of 5 cells randomly 
selected per well (n=13). ANOVA 
with Fisher’s Least Significant 






In the transwell assays, the cells with shRNA B traveled less through the pores as 
compared to the vector control (p=0.0228) (Fig. 8b). CLP36 cells migrated more than 
shRNA B, which was not quite significant, but the assay still showed that less cells 
migrating through the pore in the shRNA A (p=0.0522). Although the p value is not as 
significant, it is still close to p<0.05 and ultimately the cells with CLP36 knockdown 









Figure 8. Transwell Nuclei Count 
(A) Diagram of the transwell insert apparatus used to measure cell invasion. (B) Dot plot 
representing transwell assay cell migration. Five areas in the membrane chamber were 
selected per chamber (n=4). Cells were stained with DAPI to count the nuclei. AsPC is a 
control, mCherry N1 was selected as a vector control and CLP36-mCherry was transfected 
into AsPC cells. “A” and “B” are the knockdowns, while “F” is the control. *p=0.0522, 




To further study the localization of alpha actinin 4 and CLP36, live-cell imaging 
was performed. CLP36 and ACTN4 both localized at the same cell edges when the cell 
was migrating. CLP36 had higher expression in the cytosol than ACTN4. As the cells 
traveled on collagen, they made protrusions where both CLP36 and ACTN4 accumulated 
at the cell edge (Fig. 9a). The fluorescence was quantified by placing a yellow line across 
the cell. The intensity of fluorescence increased on the cell edges. Less fluorescence was 














Figure 9. Live Imaging 
(A) CLP36 knockdown cells were transfected with mCherry-N1-CLP36 and (B) 
GFP-ACTN4 and imaged. Cell is shown at 1.10 seconds. (C, D) Quantification of 
intensity of the fluorescence. 
B 
C D 
Distance (pixels) Distance (pixels) 




Metastatic spread of cancer cells is one of the leading cause of mortality in 
patients with pancreatic cancer. Cell migration is of huge interest in different cancer cells, 
and recent studies have shown that CLP36 expression was increased in breast cancer 
progression [59]. CLP36 in breast cancer progression lead me to want to study CLP36 in 
metastatically derived pancreatic cancer cells.  
Here I show that CLP36 is overexpressed in AsPC-1 cells as compared to non-
metastatic pancreatic cancer cell lines, and CLP36 affects cell migration. These findings 
suggest that the adaptor protein CLP36 is necessary to promote cell migration. 
Furthermore, the observations imply that targeting proteins that are overexpressed can 
have significant effects on cell migration which can affect metastatic load and ultimately 
patient survival. Additionally, other studies have shown that CLP36 binds alpha-actinin-4 
[2], a protein that has been associated with cellular motility and cancers [8]. Although 
there are interactions between CLP36 and alpha-actinin 4, it is unknown if the increase of 
CLP36 expression is involved in the progression of pancreatic cancer. The results 
demonstrate that CLP36 is an important influence for some pancreatic cancer cell 
migration in vitro.  
The scratch wound assay is one of the simplest ways to study cell migration, as it 
was useful in determining migration ability of cells or as whole cell masses. In this case, 
it was used to observe individual cell morphological characteristics and migration. The 
analysis of the scratch wound assay results shows that AsPC-1 cells migrate towards each 
other as if to close an open area. When CLP36 is knocked down, migration decreased, 
indicating that CLP36 helps the cells migrate. Measuring the distance migrated by cells 
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with CLP36 knockdown and compared to the controls, revealed specific migration 
changes and migratory phenotypes. The phenotypes observed in control cells were 
lamellipodia and cell protrusions, while in knockdowns the cells did not have protrusions 
and stayed in a sphere-like shape, not allowing the cells to migrate as much when 
compared to control cells. While the control cells formed lamellipodia where the protein 
actin was projected on the leading edge, it allowed the whole cell to propel and migrate 
against the culture environment. The cells with CLP36 knocked down appeared to 
protrude less and stayed more as a sphere. Given that higher expression of alpha-actinin 4 
functions in pancreatic cancer cell migration, it will be interesting to determine whether 
increased level of alpha-actinin 4 is affected by lower protein levels of CLP36. 
The transwell migration and invasion assays helped to assess the ability of single 
cells to migrate when CLP36 is knocked down. Fewer cells traveled through the porous 
membrane when CLP36 was knocked down, suggesting that CLP36 has a role in cell 
migration. The control (shControl) cells were unaffected in their ability to migrate 
through the pores. Since knocking down CLP36 reduced cell migration through the 
porous membrane, I hypothesize that a decrease in cell migration is happening because of 
the interaction between CLP36, actin, ACTN4 or another unknown protein interaction. 
One interesting open question is “does CLP36 interact directly with actin or other 
cytoskeleton proteins?” 
In confocal images, CLP36 and actin were concentrated and co-localized in the 
leading edges of the pancreatic cancer cells (Fig. 4), suggesting that CLP36 has a role in 
cell polarization. For the cells to move with a specific direction, they must be organizing 
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their cytoskeleton with the interaction of CLP36 to generate protrusions in the front and 
retraction in the rear.  
 
Future Directions 
Further studies should focus on protein interactions between proteins involved in 
cell migration, providing light onto cell migration and how cell migration can lead to cell 
metastasis. CLP36-mCherry C1 should be created to assess if the N1 tag position affects 
the protein itself and then compare both constructs to assess if there are any differences in 
localization, expression, and if it affects endogenous CLP36. Other cell lines like non-
metastatic pancreatic cells should be tested to test whether CLP36 promotes cell 
migration more generally. mCherry-N1-CLP36 should be transfected into other cell lines, 
specifically in non-metastatic cells to determine if overexpression of CLP36 is sufficient 
to promote migration in non-metastatic cells. All the migration assays should be 
performed in different culture environments, including 3D.  Additionally, the 
knockdowns should be rescued by expressing the CLP36 to see if migration is restored, 
thereby helping to confirm that the defect is directly due to loss of CLP36. The ability to 
rescue the knockdown will also allow for mutated versions of CLP36 to be tested. 
Possible mutants to test could include mutations that disrupt the alpha-actinin binding 
sites in CLP36 and perhaps a deletion of the PDZ domain. These mutants can then be 
used to test for their ability to interact with alpha-actinin 4 in pancreatic cancer cells. If 
the deletion of alpha-actinin 4 binding domain affects the ability of CLP36 to promote 
pancreatic cancer cell migration, this result would suggest that the binding of alpha-
actinin 4 to CLP36 is essential for the protein’s function. 
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Cell migration and invasion are important for metastasis in pancreatic cancer. To 
test whether CLP36 influences metastasis in vivo, short hairpin RNA lentiviral vectors 
that knockdown CLP36 can be used to create stable knockdown of CLP36 expression on 
pancreatic cancer cells (e.g. AsPC-1s or a mouse-derived pancreatic cancer cell line). The 
metastatic potential of the pancreatic cancer cells expressing different levels of CLP36 
could be analyzed for their ability to form metastases using mouse metastatic models.  
Such models include the hemisplenectomy assay, which tests the ability of the cells to 
form liver metastases, a primary site for pancreatic cancer metastasis formation.  In the 
future, these studies may suggest possible therapeutic approaches based on targeting 
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